Venous Ulcer Market to Witness Significant Growth by 2032 | DelveInsight

DelveInsight's report titled "Venous Leg Ulcer - Market Insight, Epidemiology And Market Forecast - 2032" [https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey regarding venous leg ulcers.

The report forecasts that the venous leg ulcer market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow at a considerable CAGR by 2032. This anticipated growth is attributed to increasing prevalence, development of novel therapies (such as stem cell therapy, growth factor therapy, and hyperbaric oxygen therapy), rising awareness, and demographic changes such as higher obesity rates, hypertension, diabetes, and sedentary lifestyles.

Download the Venous Ulcer Market report to understand which factors are driving the venous ulcer therapeutic market @ https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The report reveals that the US has the highest prevalence of venous leg ulcers among the 7MM, primarily due to lifestyle factors such as obesity and physical inactivity. VLUs represent 60-80% of all leg ulcers, with an overall prevalence between 0.18% and 1%, increasing to 4% in individuals over 65. In Europe, age-adjusted rates are elevated due to an aging population. Notably, 33-60% of VLUs become chronic, persisting for more than six weeks. These trends are projected to drive market growth during the forecast period (2025-2032).

Discover evolving trends in the venous ulcer patient pool forecasts @ https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The report also examines current venous ulcer treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs. Standard treatment methods for venous ulcers typically include compression therapy, leg elevation, wound care, and infection prevention. However, despite these interventions, venous ulcers often persist for months or even years, posing significant challenges for both patients and healthcare providers.

Most current treatments, such as, Micronized purified flavonoid fraction (MPFF), pentoxifylline, sulodexide (SDX), and mesoglycan focus on passive management rather than actively stimulating the healing process, underscoring the critical need for innovative therapeutic approaches that can accelerate wound closure and improve long-term outcomes for individuals suffering from these chronic wounds.

Merakris Therapeutics has emerged as a leader in addressing this unmet need with their biological drug, Dermacyte Liquid, also referred to as MTX-001. According to interim Phase II trial results published in March 2025, this injectable cell-free amniotic fluid has demonstrated remarkable efficacy in treating chronic, non-healing venous leg ulcers. Notably, the therapy achieved complete wound closure within one month for patients who had ulcers persisting for a median of 7 months despite prior standard interventions.

Another promising advancement comes from MTF Biologics with their AmnioBand Membrane, an aseptically processed, dehydrated human amnion/chorion allograft. A recent study demonstrated that AmnioBand achieved full wound closure in 75% of patients with chronic venous leg ulcers after just 12 weeks of treatment, making it one of the most cost-effective advanced treatment options available today.

Discover recent advancements in the venous ulcer treatment landscape @ https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

As these innovative therapies, among others, progress through clinical development, the venous skin ulcer treatment landscape is poised for significant transformation. The integration of biological, surgical, and technological approaches provides renewed hope for patients, addressing unmet needs in the field and driving market growth.

Related Reports

Venous Leg Ulcers Pipeline Insight [https://www.delveinsight.com/sample-request/venous-leg-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr]

The Venous Leg Ulcers Pipeline Insight Report provides comprehensive insights about the venous leg ulcers pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the venous leg ulcers companies, including Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, and RHEACELL, among others.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.